Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tinnitus 1Ototoxicity 1Lung Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Deafness 1

Interventions

pembrolizumab 34Cisplatin 12Nivolumab 10atezolizumab 9Docetaxel 9Carboplatin 9Paclitaxel 8Cetuximab 8Gemcitabine 7Blood Specimen Collection 7Radiotherapy 6Fluorouracil 6Drug Therapy 6cemiplimab 5Pemetrexed 5Immune Checkpoint Inhibitors 5fludarabine 4Standard of Care 4Cyclophosphamide 4spartalizumab 3epacadostat 3Surveys and Questionnaires 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Interleukin-2 3Filgrastim 3Bupropion 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × ebselen × Thoracic × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡